Gabriel Cohn's most recent trade in Q32 Bio Inc. was a trade of 4,290 Restricted Stock Units done . Disclosure was reported to the exchange on Jan. 1, 2022.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Q32 Bio Inc. | Gabriel Cohn | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 8,710 | - | - | Restricted Stock Units | |
Q32 Bio Inc. | Gabriel Cohn | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 4,290 | 4,290 (0%) | 0% | - | Common Stock | |
Q32 Bio Inc. | Gabriel Cohn | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 1,661 | 2,629 (0%) | 0% | 3.8 | 6,279 | Common Stock |
Q32 Bio Inc. | Gabriel Cohn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 78,000 | 78,000 | - | - | Employee Stock Option (Right to Buy) | |
Q32 Bio Inc. | Gabriel Cohn | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 13,000 | 13,000 | - | - | Restricted Stock Units |